Boosting immune cells to fight chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study looks at how a protein called ANKRD11 affects immune cells that fight hepatitis B. It aims to see if targeting this protein can help those cells work better to control the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have had hepatitis B (HBsAg positive) for at least 6 months
- You have a specific genetic marker called HLA-A11
- You do not have other liver diseases like cirrhosis, cancer, or autoimmune hepatitis
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.